Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Molecular Remission by ASO-RQ-PCR Technique After Induction Treatment With Bortezomib-Dexamethasone (Vel/Dex) Followed by HDT With ASCT

Next Previous
Trial Profile

Assessment of Molecular Remission by ASO-RQ-PCR Technique After Induction Treatment With Bortezomib-Dexamethasone (Vel/Dex) Followed by HDT With ASCT

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 30 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use

Most Recent Events

  • 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 10 May 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
  • 17 Feb 2012 Planned end date changed from 1 Jul 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top